DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/h9xjdl/lung_cancer) has announced the addition of the "Lung Cancer Partnering 2009-2014" report to their offering.
The report provides an analysis of lung cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lung cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This data driven report contains over 200 links to online copies of actual lung cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Lung Cancer Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to lung cancer trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in lung cancer dealmaking in the biopharma industry since 2009
- Access to summary headline, upfront, milestone and royalty data
- Access to over 200 lung cancer contract documents
- The leading lung cancer deals by value since 2009
In Lung Cancer Partnering 2009-2014, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
For more information visit http://www.researchandmarkets.com/research/h9xjdl/lung_cancer